
Roche Bobois Group
Roche Bobois
Roche Bobois Group is a high-end luxury furniture brand operator headquartered in Paris, France, and listed on Euronext Paris. Specializing in luxury indoor/outdoor furniture, home accessories, and design services, it leverages authentic French design, exquisite craftsmanship, and a direct-to-retail model, operating in 45 countries globally. With approximately 260 brand galleries and 1,200 employees, it reported revenue of €350 million in 2024. Its competitive edge in the global high-end furniture market stems from exceptional design value, masterful handcrafted quality, and a distinct luxury brand positioning.
Strengths: Roche Bobois' core strengths are its exceptional French design capabilities, maintained through collaborations with international designers ensuring innovation; masterful handcrafted quality using premium materials and traditional techniques; and clear luxury positioning with a global direct retail network across 45 countries.
Weaknesses: Roche Bobois faces intensifying competition in the luxury segment; its handmade production limits scalability and expansion pace; its high-end positioning makes it vulnerable to economic fluctuations affecting demand stability; and its relatively niche market scale constrains rapid revenue growth potential.Read More ▼Show Less ▲
Strengths: Roche Bobois' core strengths are its exceptional French design capabilities, maintained through collaborations with international designers ensuring innovation; masterful handcrafted quality using premium materials and traditional techniques; and clear luxury positioning with a global direct retail network across 45 countries.
Weaknesses: Roche Bobois faces intensifying competition in the luxury segment; its handmade production limits scalability and expansion pace; its high-end positioning makes it vulnerable to economic fluctuations affecting demand stability; and its relatively niche market scale constrains rapid revenue growth potential.
Business Nature
15 pharmaceutical plants, 20 diagnostics plants, 30 R&D centers worldwide. Operations across 150+ countries.
101,000 employees, 15,000+ R&D staff. CHF 63B revenue FY2025. CHF 12B R&D investment. 140+ pipeline projects, 50,000+ active patents.
Core Business Areas
• Pharmaceuticals 2.1-2.17 — Core Business: Innovative drugs in oncology, immunology, neuroscience, rare diseases; biologics including monoclonal antibodies and small molecule drugs
• Diagnostics 5.1-5.9, 6.1-6.7 — Key Business: In vitro diagnostics, tissue diagnostics, diabetes management, personalized healthcare, companion diagnostics, molecular diagnostics
• Other Operations 7.1-7.7 — Supporting services and healthcare solutions
Industry Rankings
Corporate Report
VerityRank Score
Based on market presence, financial scale, operational capacity, and brand strength.
Quick Facts
Headquarters
Basel, Switzerland
Founded
1960
Employees
1.2K+
Listing
Publicly Listed
Categories
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Euronext Paris:RBO
